A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

Oncologist · 2019 · PMC6738313 · PMID 31171735

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Biomarker analyses in the present study showed a trend toward lower baseline levels of HGF, IL‐8, NGAL, TIMP1, and VEGFR3 associating with better radiographic responses.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.